NIH supports genome editing and other biologic therapies for Alzheimer's disease-related dementias, from lead optimization and drug development through safety studies and early clinical evaluation.
Funder: National Institutes of Health
Due Dates: February 9, 2027 (Applications) | October 6, 2027 (Applications) | October 10, 2028 (Applications / Final closing)
Funding Amounts: Up to $1.3 million in annual direct costs, or $2.5 million with a Phase 1 first-in-human trial; up to 5 years
Summary: Supports milestone-driven translation of genome editing and other biologic therapies for Alzheimer's disease-related dementias toward IND-enabling development and early clinical evaluation.
Key Information: Projects need a defined therapeutic candidate and translational path; basic disease-mechanism research is not responsive.
NIH's National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA) support multidisciplinary teams advancing genome editing and other biologic therapies for Alzheimer's disease-related dementias (ADRD). This U01 cooperative agreement covers therapeutic lead optimization, drug product development, IND-enabling studies, and, where justified, early clinical evaluation.
Eligible disease areas include frontotemporal dementia; Lewy body dementias, including dementia with Lewy bodies and Parkinson's disease dementia; vascular contributions to cognitive impairment and dementia; and multiple etiology dementias. Supported work includes delivery-system optimization, target engagement, pharmacokinetics, durability, in vivo efficacy, safety and toxicology, scalable manufacturing, and regulatory preparation. Projects must define quantitative development parameters and annual milestones with Go/No-Go criteria. Clinical trials are optional and should focus on first-in-human safety, tolerability, pharmacokinetics, pharmacodynamics, and target engagement.